Alla studier
RekryteringTerapeutisk utforskande (Fas II)Interventionell

A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by subcutaneous injection in nonambulatory participants with Duchenne Muscular Dystrophy

This research study is testing a new medicine called ATL1102 for boys living with Duchenne Muscular Dystrophy (DMD) who can no longer walk. The main goal is to find out if ATL1102 can help improve the use of their arms and hands, and how safe it is to use. Participants will be given either ATL1102 or a placebo (a dummy medicine) through injections under the skin. Initially, no one will know who is getting which. After a period, all participants will have the chance to receive ATL1102 in an 'open-label' part of the study. Researchers will carefully check muscle strength, how well arms and hands work, and monitor for any side effects.

Överblick

Status
Rekrytering
Fas
Terapeutisk utforskande (Fas II)
Sponsor
Antisense Therapeutics Limited
Inskrivningsmål
1
Starta
30 juli 2024

Vad handlar denna studie om?

This study is a medical investigation into a new potential treatment called ATL1102 for Duchenne Muscular Dystrophy (DMD). DMD is a serious condition that causes muscles to weaken over time. This particular study is focusing on boys with DMD who are no longer able to walk. The medicine, ATL1102, is designed to be given as an injection just under the skin.

The main purpose of this research is to see if ATL1102 can help improve how well the participants can use their arms and hands. This is measured using a special system called the Performance of Upper Limb (PUL 2.0) score. The researchers also want to thoroughly check how safe the medicine is by carefully looking for any side effects or changes in health.

This study is divided into different stages. In the first part, some participants will receive ATL1102, while others will receive a placebo – a substance that looks exactly like the medicine but contains no active drug. Neither the participants, their families, nor the study doctors will know who is getting which. This helps make sure the results are fair. After this first stage, everyone will have the chance to receive the ATL1102 medicine in an 'open-label' part of the study, where everyone knows what treatment they are getting. This type of study helps scientists understand if new medicines are both helpful and safe.

Viktiga punkter

  • This study investigates a new medicine (ATL1102) for boys with Duchenne Muscular Dystrophy who can't walk.
  • The main goals are to check if the medicine helps improve arm and hand function, and if it's safe.
  • Participants will receive either ATL1102 or a placebo by injection in the first phase.
  • Everyone will eventually have the chance to receive the active medicine.
  • Regular clinic visits will involve assessments of muscle function, heart, breathing, and blood tests.
  • Your safety will be closely monitored throughout the study.

Vem kan vara berättigad?

This study is specifically looking for boys who have Duchenne Muscular Dystrophy.

To be considered for this study, participants must no longer be able to walk. There are no specific age limits mentioned, meaning boys of varying ages who meet the other criteria might be able to take part.

It's important to remember that this is just a quick overview. If you or someone you know might be interested, a doctor involved in the study would need to check all the detailed requirements to see if it's a suitable fit. They will make sure it's safe and appropriate for everyone who joins.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Do you have a diagnosis of Duchenne Muscular Dystrophy?
  2. Are you a male?
  3. Are you no longer able to walk?
  4. Are you willing to attend regular clinic appointments for over 11 months?
  5. Are you comfortable with receiving injections under the skin?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you would receive the study medicine (or placebo initially) as an injection under the skin. These injections would be given regularly over many weeks.

Throughout the study, you would have regular visits to the clinic. At these visits, doctors and nurses would perform various checks. This includes tests to see how well you can use your arms and hands, and to measure your muscle strength. They would also take blood and urine samples, check your heart with tests like an ECG (a heart tracing) and an echocardiogram (an ultrasound of the heart), check your breathing, and perform general physical examinations.

Your vital signs, such as blood pressure, heart rate, and temperature, would also be regularly monitored. The study will run for about 49 weeks (around 11-12 months) in total, with the first 25 weeks being the 'blinded' part and the remaining weeks being the 'open-label' part. Throughout, your safety will be closely watched.

Potentiella risker och fördelar

Taking part in this study might offer the potential benefit of improving the use of your arms and hands, or at least slowing down any decline. This is what the researchers hope to find out. However, like all medicines, ATL1102 could have side effects, which might range from mild reactions at the injection site to more serious, but rare, problems. The research team will carefully monitor you for any changes in your health. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Platser (1)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Bulgarien

Vanliga frågor

What is Duchenne Muscular Dystrophy?

Duchenne Muscular Dystrophy (DMD) is a genetic condition that causes muscles to become weaker over time.

What is ATL1102?

ATL1102 is a new medicine being tested as a potential treatment for Duchenne Muscular Dystrophy.

What does a 'placebo' mean?

A placebo is a dummy medicine that looks just like the real medicine but contains no active drug. It helps researchers compare results fairly.

Kommer jag att veta om jag får den riktiga medicinen?

Initially, no one (you, your family, or the study doctors) will know. Later in the study, everyone will receive the active medicine.

Hur ges medicinen?

The medicine is given by an injection just under the skin (subcutaneous injection).

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A multicentre, randomised, double-blind, placebo-controlled …" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.